Health Care & Life Sciences » Pharmaceuticals | Amarillo Biosciences Inc.

Amarillo Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
250.90
77.70
Cost of Goods Sold (COGS) incl. D&A
16.10
17.50
19.80
26.00
100.30
121.10
Gross Income
16.10
17.50
19.80
26.00
150.60
43.30
SG&A Expense
550.00
563.70
500.00
641.20
730.40
1,291.30
EBIT
566.20
581.30
-
667.10
579.80
1,334.70
Unusual Expense
46.90
-
-
-
-
-
Interest Expense
103.40
1.90
2.10
2.90
37.60
4
Pretax Income
622.60
2,839.70
521.90
670.00
617.40
1,338.60
Consolidated Net Income
622.60
2,839.70
521.90
670.00
617.40
1,338.60
Net Income
622.60
2,839.70
521.90
670.00
617.40
1,338.60
Net Income After Extraordinaries
622.60
2,839.70
521.90
670.00
617.40
1,338.60
Net Income Available to Common
655.00
2,810.80
521.90
670.00
617.40
1,338.60
EPS (Basic)
0.17
0.14
0.03
0.03
0.03
0.04
Basic Shares Outstanding
3,865.50
20,144.80
20,144.80
21,055.90
22,663.50
35,643.80
EPS (Diluted)
0.17
0.14
0.03
0.03
0.03
0.04
Diluted Shares Outstanding
3,865.50
20,144.80
20,144.80
21,055.90
22,663.50
35,643.80
EBITDA
550.00
563.70
500.10
641.20
539.80
1,278.50
Preferred Dividends
32.40
28.90
-
-
-
-

About Amarillo Biosciences

View Profile
Address
4134 Business Park Drive
Amarillo Texas 79110
United States
Employees -
Website http://www.amarbio.com
Updated 07/08/2019
Amarillo Biosciences, Inc. engages in developing biologics for the treatment of human and animal diseases. It focuses on research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. The company was founded by Joseph M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.